Healthcare

Their 2026 disclosures show that commercial adoption is now as important as product development. Orthocell is expanding Remplir across US hospitals, PolyNovo is seeking further growth from NovoSorb BTM and the newer MTX format, while Aroa is increasingInvestmentin direct sales as it expands Myriad …

Their financial positions differ considerably. Argenica remains an early-stage developer with limited cash relative to future trial requirements, Neuren has an establishedRoyaltystream and substantial liquidity, while PYC completed a significantCapitalraising during 2026 to support clinical development.

Their latest financial results show three different stages of commercial development. Cyclopharm is increasing USRevenuewhile remaining loss-making, Medical Developments has returned to modest profitability and positive cash generation, while Nova Eye continues to expand sales and has moved toward positive EBITDA despite a relatively …

After aTrading halton 2 September, Dimerix announced on 4 September 2026 a A$34 million non-dilutive funding facility from Australian and United States lenders. Half, or A$17 million, was to be drawn by 18 September 2026, with the balance available at the company's discretion until …

The most recent disclosure is procedural, but it says something about how management is deploying capital. In an update lodged on 10 September 2026, Vita Life Sciences reported buying 4,099 shares on market the previous day at A$2.76 each, for consideration of A$11,426.37.

The most significant recent step is in the United Kingdom. Alcidion's own news material, accessed on 11 September 2026, records that University Hospitals Sussex NHS Foundation Trust has signed a seven-year contract with the company. Market data compiled by Small Caps and accessed the …

It reported half-year accounts in late August 2026 and carried aMarket Capitalisationof about A$143 million as at 11 September 2026. For an ASX-listed healthcare technology name of this size, the question is whether revenue growth can outrun a persistent operating loss.